GET DAILY SIGNALSAutolus (AUTL) vs CRISPR (CRSP): Commercial Momentum Versus Platform Breadth
Key Takeaways
- AUTL is a commercial-stage cell therapy company gaining revenue traction, while CRSP remains earlier-stage with a far larger cash position and a broader pipeline.
- AUTL has transitioned to positive gross margins and raised its 2026 revenue guidance, whereas CRSP still reports minimal top-line revenue from its Casgevy profit share.
- CRSP carries a much larger market capitalization and balance sheet, but also deeper ongoing losses and a longer path to profitability.
- The two names offer contrasting risk profiles: a commercial launch story versus a diversified gene-editing platform with multiple clinical catalysts.
- For more context on each name, visit the AUTL Major News and AUTL Today's Price Move pages, along with the CRSP Major News and CRSP Today's Price Move pages.
- To see how automated systems are positioning across these and other tickers, explore the curated Trending AI Robots section.
Setting the Stage
This comparison examines two biotechnology companies operating in overlapping yet distinct areas of the cell and gene therapy landscape. Autolus Therapeutics (AUTL) has already commercialized a T-cell therapy for a blood cancer, while CRISPR Therapeutics (CRSP) is building a gene-editing platform around the first approved CRISPR-based therapy. Investors evaluating growth-stage biotech often weigh a near-term commercial ramp against a longer-dated, broader pipeline, and this stock comparison highlights that trade-off. The analysis is most relevant to traders and long-term investors assessing relative performance, market positioning, and risk in the evolving cell and gene therapy sector. I also checked this using Tickeron’s AI Screener to see how the stocks compare to others in the industry.
Autolus Therapeutics (AUTL): Commercial Progress in Focus
Autolus Therapeutics is a commercial-stage biopharmaceutical company developing programmed T-cell therapies. Its marketed product, AUCATZYL (obe-cel), is approved for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), a form of blood cancer. Recent market activity has reflected improving commercial execution: quarterly product revenue climbed roughly 119% year over year to about $45.7 million, and management raised full-year 2026 net product revenue guidance to a range of $140 million to $150 million.
Gross margin turned positive and reached approximately 55% in the most recent quarter, a notable shift for a company that previously reported losses across quarters. Sentiment has also been shaped by cost discipline, including a workforce reduction of about 13%, and a financing facility of up to $250 million. Key catalysts include longer-term data from the CARLYSLE trial in refractory lupus and initial AUTO8 data in light-chain amyloidosis, both expected by year-end. The shares have traded in a broad range, underscoring the volatility typical of smaller-cap biotech.
CRISPR Therapeutics (CRSP): Platform Potential and Balance Sheet Strength
CRISPR Therapeutics is a gene-editing company built on the CRISPR/Cas9 platform. Its flagship therapy, Casgevy, developed with Vertex Pharmaceuticals, is approved in the United States and Europe for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). Under the partnership, Vertex leads commercialization and the two companies share costs and profits on a 60/40 basis. Recent momentum has centered on Casgevy's uptake, with Vertex recording sequential and year-over-year sales growth, plus label expansion to younger patients.
Financially, CRSP reports a relatively small top line, with collaboration revenue of about $10.2 million in the most recent quarter, alongside a net loss that has narrowed from a year earlier. The company holds a substantial cash position of roughly $2.36 billion, supporting a diversified pipeline that includes CTX310 for cardiovascular indications and zugo-cel, an investigational allogeneic CAR-T therapy. Analysts broadly maintain a positive consensus rating, though shares have lagged the broader market year to date, reflecting continued clinical and commercial execution risk. From what I see, Tickeron’s AI Trend Prediction Engine points to steady but measured interest in the name.
Head-to-Head Comparison
The core contrast between these two stocks is the maturity of their commercial franchises. AUTL is executing a focused launch and expanding margins, but its business is concentrated on a single marketed therapy and a narrower indication set, with a modest cash runway relative to its larger peer. CRSP offers broader platform optionality across hematology, cardiovascular, and autoimmune disease, backed by a much larger cash balance, yet it remains deeply unprofitable with minimal reported revenue.
Growth drivers also differ: AUTL's near-term story hinges on AUCATZYL adoption and pipeline readouts in lupus and amyloidosis, while CRSP's narrative depends on Casgevy's ramp and multiple clinical milestones. Risk factors diverge accordingly, with AUTL exposed to reimbursement and manufacturing scale-up, and CRSP exposed to clinical trial outcomes and dilution from convertible financing. Sector exposure overlaps in cell therapy, but CRSP's gene-editing platform spans a wider therapeutic base.
AI Tools in My Research Process
In my research, I often turn to Tickeron’s AI Trading Bots to see how automated strategies are handling names like these. The platform hosts hundreds of bots across different styles and timeframes, and the trending section highlights those performing best in current conditions. It gives a useful perspective on how algorithmic models are positioning across AUTL, CRSP, and similar securities without replacing fundamental analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CRSP sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for CRSP moved above the 200-day moving average on September 23, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 65 cases where CRSP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
Following a +2.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRSP advanced for three days, in 209 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
CRSP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CRSP as a result. In 76 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.
The Moving Average Convergence Divergence Histogram (MACD) for CRSP turned negative on October 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 39 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
CRSP moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CRSP crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 60%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRSP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for CRSP entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.849) is normal, around the industry mean (3.037). P/E Ratio (-10.928) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (454.545) is also within normal values, averaging (439.237).
The Tickeron PE Growth Rating for this company is 46 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. CRSP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRSP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of gene-based medicines
Industry Biotechnology
Advertisement